Lmcg Investments LLC trimmed its holdings in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 21.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 118,397 shares of the company's stock after selling 31,537 shares during the quarter. Lmcg Investments LLC owned 0.06% of Doximity worth $6,871,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Doximity by 4.5% during the fourth quarter. Vanguard Group Inc. now owns 11,203,569 shares of the company's stock valued at $598,159,000 after purchasing an additional 485,102 shares during the last quarter. FMR LLC increased its holdings in shares of Doximity by 37.6% in the fourth quarter. FMR LLC now owns 9,409,313 shares of the company's stock valued at $502,363,000 after buying an additional 2,571,580 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Doximity by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 2,952,442 shares of the company's stock valued at $157,668,000 after buying an additional 95,458 shares in the last quarter. Loomis Sayles & Co. L P lifted its position in shares of Doximity by 2.7% during the 4th quarter. Loomis Sayles & Co. L P now owns 2,334,597 shares of the company's stock valued at $124,644,000 after acquiring an additional 62,366 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Doximity by 9.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,847,702 shares of the company's stock worth $98,649,000 after acquiring an additional 164,200 shares in the last quarter. Institutional investors own 87.19% of the company's stock.
Doximity Stock Up 2.6%
Shares of DOCS traded up $1.49 during mid-day trading on Friday, hitting $58.83. 2,014,061 shares of the company's stock were exchanged, compared to its average volume of 2,119,986. Doximity, Inc. has a twelve month low of $25.00 and a twelve month high of $85.21. The firm has a fifty day moving average of $54.68 and a two-hundred day moving average of $58.11. The stock has a market cap of $11.05 billion, a price-to-earnings ratio of 58.83, a P/E/G ratio of 4.10 and a beta of 1.32.
Doximity (NASDAQ:DOCS - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.11. Doximity had a return on equity of 21.75% and a net margin of 36.60%. The company's quarterly revenue was up 17.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.25 EPS. On average, equities analysts predict that Doximity, Inc. will post 0.99 earnings per share for the current year.
Wall Street Analyst Weigh In
DOCS has been the subject of several analyst reports. The Goldman Sachs Group set a $50.00 target price on Doximity and gave the company a "neutral" rating in a report on Wednesday, May 21st. William Blair reaffirmed an "outperform" rating on shares of Doximity in a research note on Friday, May 16th. JPMorgan Chase & Co. decreased their target price on shares of Doximity from $63.00 to $60.00 and set a "neutral" rating for the company in a report on Tuesday, May 27th. Canaccord Genuity Group cut their price target on shares of Doximity from $71.00 to $50.00 and set a "hold" rating on the stock in a report on Friday, May 16th. Finally, KeyCorp decreased their price objective on shares of Doximity from $83.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. Eleven analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Doximity presently has a consensus rating of "Moderate Buy" and an average price target of $62.84.
Get Our Latest Stock Analysis on DOCS
Insider Activity
In other news, CFO Anna Bryson sold 45,000 shares of the company's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $57.23, for a total transaction of $2,575,350.00. Following the completion of the transaction, the chief financial officer now owns 357,165 shares of the company's stock, valued at approximately $20,440,552.95. This represents a 11.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kira Scherer Wampler sold 2,000 shares of Doximity stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $52.89, for a total value of $105,780.00. Following the sale, the director now directly owns 16,618 shares in the company, valued at approximately $878,926.02. This trade represents a 10.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 51,000 shares of company stock valued at $2,900,770 over the last 90 days. 37.40% of the stock is currently owned by company insiders.
Doximity Profile
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Featured Stories

Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report